Literature DB >> 8207810

Epstein-Barr virus recombinant molecular genetic analysis of the LMP1 amino-terminal cytoplasmic domain reveals a probable structural role, with no component essential for primary B-lymphocyte growth transformation.

K M Izumi1, K M Kaye, E D Kieff.   

Abstract

Previous recombinant Epstein-Barr virus molecular genetic experiments with specifically mutated LMP1 genes indicate that LMP1 is essential for primary B-lymphocyte growth transformation and that the amino-terminal cytoplasmic and first transmembrane domains are together an important mediator of transformation. EBV recombinants with specific deletions in the amino-terminal cytoplasmic domain have now been constructed and tested for the ability to growth transform primary B lymphocytes into lymphoblastoid cell lines. Surprisingly, deletion of DNA encoding EHDLER or GPPLSSS from the full LMP1 amino-terminal cytoplasmic domain (MEHDLERGPPGPRRPPRGPPLSSS) had no discernible effect on primary B-lymphocyte transformation. These two motifs distinguish the LMP1 amino-terminal cytoplasmic domain from other arginine-rich membrane proximal sequences that anchor hydrophobic transmembrane domains. Two deletions which included the ERGPPGPRRPPR motif adversely affected but did not prevent transformation. This arginine- and proline-rich sequence is probably important in anchoring the first transmembrane domain in the plasma membrane, since these mutated LMP1s had altered stability and cell membrane localization. The finding that overlapping deletions of the entire amino-terminal cytoplasmic domain do not ablate transformation is most consistent with a model postulating that the transmembrane and carboxyl-terminal cytoplasmic domains are the likely biochemical effectors of transformation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8207810      PMCID: PMC236360     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  Covalently closed circular duplex DNA of Epstein-Barr virus in a human lymphoid cell line.

Authors:  T Lindahl; A Adams; G Bjursell; G W Bornkamm; C Kaschka-Dierich; U Jehn
Journal:  J Mol Biol       Date:  1976-04-15       Impact factor: 5.469

2.  Epstein-Barr virus genomes with properties of circular DNA molecules in carrier cells.

Authors:  A Adams; T Lindahl
Journal:  Proc Natl Acad Sci U S A       Date:  1975-04       Impact factor: 11.205

3.  Persisting oncogenic herpesvirus induced by the tumour promotor TPA.

Authors:  H zur Hausen; F J O'Neill; U K Freese; E Hecker
Journal:  Nature       Date:  1978-03-23       Impact factor: 49.962

4.  Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes.

Authors:  G Miller; T Shope; H Lisco; D Stitt; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1972-02       Impact factor: 11.205

5.  DNA sequence and expression of the B95-8 Epstein-Barr virus genome.

Authors:  R Baer; A T Bankier; M D Biggin; P L Deininger; P J Farrell; T J Gibson; G Hatfull; G S Hudson; S C Satchwell; C Séguin
Journal:  Nature       Date:  1984 Jul 19-25       Impact factor: 49.962

6.  Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation.

Authors:  K M Kaye; K M Izumi; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

7.  Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein.

Authors:  S Fennewald; V van Santen; E Kieff
Journal:  J Virol       Date:  1984-08       Impact factor: 5.103

8.  Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection, and interference.

Authors:  G Miller; J Robinson; L Heston; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1974-10       Impact factor: 11.205

9.  A membrane protein encoded by Epstein-Barr virus in latent growth-transforming infection.

Authors:  K Hennessy; S Fennewald; M Hummel; T Cole; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

10.  Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells.

Authors:  W Henle; V Diehl; G Kohn; H Zur Hausen; G Henle
Journal:  Science       Date:  1967-09-01       Impact factor: 47.728

View more
  29 in total

1.  The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptor-interacting protein (RIP) but does not induce apoptosis or require RIP for NF-kappaB activation.

Authors:  K M Izumi; E D Cahir McFarland; A T Ting; E A Riley; B Seed; E D Kieff
Journal:  Mol Cell Biol       Date:  1999-08       Impact factor: 4.272

Review 2.  The genetic approach to the Epstein-Barr virus: from basic virology to gene therapy.

Authors:  H J Delecluse; W Hammerschmidt
Journal:  Mol Pathol       Date:  2000-10

3.  Transmembrane Domains Mediate Intra- and Extracellular Trafficking of Epstein-Barr Virus Latent Membrane Protein 1.

Authors:  Dingani Nkosi; Lauren A Howell; Mujeeb R Cheerathodi; Stephanie N Hurwitz; Deanna C Tremblay; Xia Liu; David G Meckes
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

4.  Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein.

Authors:  K M Kaye; O Devergne; J N Harada; K M Izumi; R Yalamanchili; E Kieff; G Mosialos
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

5.  The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation.

Authors:  K M Izumi; K M Kaye; E D Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

6.  Epstein-Barr virus vectors for gene delivery to B lymphocytes.

Authors:  E S Robertson; T Ooka; E D Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

7.  TRAF6 is a critical mediator of signal transduction by the viral oncogene latent membrane protein 1.

Authors:  U Schultheiss; S Püschner; E Kremmer; T W Mak; H Engelmann; W Hammerschmidt; A Kieser
Journal:  EMBO J       Date:  2001-10-15       Impact factor: 11.598

8.  Stimulation of NF-kappa B-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus.

Authors:  T Mitchell; B Sugden
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

9.  Nucleotide sequences and functions of the Epstein-Barr virus latent membrane protein 1 genes isolated from salivary gland lymphoepithelial carcinomas.

Authors:  Kai Yu Jen; Masaya Higuchi; Jun Cheng; Jiang Li; Lan Yan Wu; Ying Fang Li; Han Liang Lin; Zhilong Chen; Vladimir Gurtsevitch; Masahiro Fujii; Takashi Saku
Journal:  Virus Genes       Date:  2005-03       Impact factor: 2.332

10.  Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-kappaB through a pathway that includes the NF-kappaB-inducing kinase and the IkappaB kinases IKKalpha and IKKbeta.

Authors:  B S Sylla; S C Hung; D M Davidson; E Hatzivassiliou; N L Malinin; D Wallach; T D Gilmore; E Kieff; G Mosialos
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.